ArticleHealth science reports2026
Increased Serum TNF-α Levels Are Associated With Generalized Anxiety Disorder: A Case-Control Study.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Generalized anxiety disorder (GAD) is a mental health disorder that affects many people in all aspects of their lives. It is characterized by persistent and excessive worry that the affected person finds difficult to control. The actual pathophysiology and mechanisms underlying GAD are still elusive. However, cytokines and cell signaling proteins are hypothesized to contribute to the pathogenesis of anxiety. The present study aimed to understand the association of tumor necrosis factor-α (TNF-α) in the pathophysiology of GAD. Methods: This case-control study recruited 43 GAD patients and 26 healthy controls (HCs) matched by age, sex, and other demographic factors. A clinical psychiatrist diagnosed patients and evaluated controls according to DSM-5 criteria. The GAD-7 scale was used to measure the severity of GAD symptoms. Serum TNF-α levels were measured using enzyme-linked immunosorbent assay (ELISA), and appropriate statistical methods were applied to find the associations among the analyzed parameters. Results: The results showed that TNF-α levels in GAD patients were significantly elevated than in HCs. The increased TNF-α levels were positively correlated with the severity of GAD symptoms. Moreover, the ROC curve reveals the AUC, sensitivity, and specificity as 0.888 (95% CI: 0.810-0.966), 84.6%, and 83.3%, respectively, at a cut-off value of 50.86 pg/ml. These results suggest a potential role of TNF-α in the pathophysiology and development of GAD. Conclusion: These findings indicate the role of cytokine dysregulation in GAD pathogenesis. This research advances the understanding of the immune system's association with GAD. However, as this was a cross-sectional case-control study, TNF-α should at present be regarded as a candidate biomarker that needs validation in larger and longer-term studies before it can be used clinically.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.